XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis
USA - NASDAQ:XOMA - US98419J2069 - Common Stock
35.17 USD
+0.9 (+2.63%)
XOMA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While XOMA is still in line with the averages on profitability rating, there are concerns on its financial health. XOMA has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
XOMA had negative earnings in the past year.
XOMA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
In multiple years XOMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of -7.93%, XOMA belongs to the best of the industry, outperforming 85.02% of the companies in the same industry.
Looking at the Return On Equity, with a value of -19.17%, XOMA belongs to the top of the industry, outperforming 84.46% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.73%, XOMA belongs to the top of the industry, outperforming 91.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| ROIC | 3.73% |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XOMA's Operating Margin of 21.23% is amongst the best of the industry. XOMA outperforms 94.76% of its industry peers.
XOMA does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.23% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XOMA is destroying value.
The number of shares outstanding for XOMA has been increased compared to 1 year ago.
XOMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XOMA is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.96, we must say that XOMA is in the distress zone and has some risk of bankruptcy.
XOMA's Altman-Z score of -4.96 is on the low side compared to the rest of the industry. XOMA is outperformed by 61.24% of its industry peers.
A Debt/Equity ratio of 1.11 is on the high side and indicates that XOMA has dependencies on debt financing.
The Debt to Equity ratio of XOMA (1.11) is worse than 77.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.96 |
ROIC/WACC0.39
WACC9.66%
2.3 Liquidity
A Current Ratio of 4.88 indicates that XOMA has no problem at all paying its short term obligations.
XOMA has a Current ratio of 4.88. This is comparable to the rest of the industry: XOMA outperforms 52.81% of its industry peers.
A Quick Ratio of 4.88 indicates that XOMA has no problem at all paying its short term obligations.
XOMA's Quick ratio of 4.88 is in line compared to the rest of the industry. XOMA outperforms 54.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.88 | ||
| Quick Ratio | 4.88 |
3. Growth
3.1 Past
The earnings per share for XOMA have decreased strongly by -38.74% in the last year.
The Revenue has grown by 168.71% in the past year. This is a very strong growth!
Measured over the past years, XOMA shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
3.2 Future
Based on estimates for the next years, XOMA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
Based on estimates for the next years, XOMA will show a very strong growth in Revenue. The Revenue will grow by 35.53% on average per year.
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
XOMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 68.52, XOMA can be considered very expensive at the moment.
88.20% of the companies in the same industry are more expensive than XOMA, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.99. XOMA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 68.52 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XOMA is valued cheaper than 91.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 40.74 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.97%
EPS Next 3Y37.32%
5. Dividend
5.1 Amount
XOMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:XOMA (10/24/2025, 8:02:56 PM)
35.17
+0.9 (+2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners68.05%
Inst Owner Change0%
Ins Owners1.4%
Ins Owner Change-11.59%
Market Cap425.21M
Revenue(TTM)44.95M
Net Income(TTM)-17720000
Analysts82
Price Target71.06 (102.05%)
Short Float %2.18%
Short Ratio4.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)0%
PT rev (3m)7.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)72.73%
EPS NY rev (1m)0%
EPS NY rev (3m)371.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 68.52 | ||
| P/S | 9.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.6 | ||
| P/tB | 9.04 | ||
| EV/EBITDA | 40.74 |
EPS(TTM)-1.54
EYN/A
EPS(NY)0.51
Fwd EY1.46%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| ROCE | 4.73% | ||
| ROIC | 3.73% | ||
| ROICexc | 6.38% | ||
| ROICexgc | 10.37% | ||
| OM | 21.23% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 9.33 | ||
| Cap/Depr | 1425.07% | ||
| Cap/Sales | 44.89% | ||
| Interest Coverage | 0.78 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.88 | ||
| Quick Ratio | 4.88 | ||
| Altman-Z | -4.96 |
F-Score5
WACC9.66%
ROIC/WACC0.39
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.34%
EBIT Next 3Y51.87%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A
XOMA ROYALTY CORPORATION / XOMA FAQ
Can you provide the ChartMill fundamental rating for XOMA ROYALTY CORPORATION?
ChartMill assigns a fundamental rating of 4 / 10 to XOMA.
Can you provide the valuation status for XOMA ROYALTY CORPORATION?
ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORPORATION (XOMA). This can be considered as Fairly Valued.
How profitable is XOMA ROYALTY CORPORATION (XOMA) stock?
XOMA ROYALTY CORPORATION (XOMA) has a profitability rating of 4 / 10.
What is the expected EPS growth for XOMA ROYALTY CORPORATION (XOMA) stock?
The Earnings per Share (EPS) of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 126.86% in the next year.